DE69520943D1 - Malariapeptide - Google Patents
MalariapeptideInfo
- Publication number
- DE69520943D1 DE69520943D1 DE69520943T DE69520943T DE69520943D1 DE 69520943 D1 DE69520943 D1 DE 69520943D1 DE 69520943 T DE69520943 T DE 69520943T DE 69520943 T DE69520943 T DE 69520943T DE 69520943 D1 DE69520943 D1 DE 69520943D1
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- hla
- microorganism
- peptides
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 244000005700 microbiome Species 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101710145634 Antigen 1 Proteins 0.000 abstract 1
- 101710117490 Circumsporozoite protein Proteins 0.000 abstract 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 108010013698 HLA-B17 antigen Proteins 0.000 abstract 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 abstract 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 101710104031 Thrombospondin-related anonymous protein Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9406492A GB9406492D0 (en) | 1994-03-31 | 1994-03-31 | Malaria peptides |
| PCT/GB1995/000737 WO1995026982A2 (en) | 1994-03-31 | 1995-03-30 | Malaria peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69520943D1 true DE69520943D1 (de) | 2001-06-21 |
| DE69520943T2 DE69520943T2 (de) | 2001-11-08 |
Family
ID=10752882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69520943T Expired - Fee Related DE69520943T2 (de) | 1994-03-31 | 1995-03-30 | Malariapeptide |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0753009B1 (de) |
| JP (2) | JPH09510877A (de) |
| AT (1) | ATE201215T1 (de) |
| DE (1) | DE69520943T2 (de) |
| GB (1) | GB9406492D0 (de) |
| WO (1) | WO1995026982A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| US6413517B1 (en) * | 1997-01-23 | 2002-07-02 | Epimmune, Inc. | Identification of broadly reactive DR restricted epitopes |
| US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| NZ530723A (en) | 2001-07-02 | 2006-02-24 | Bioincept Llc | New assays for PFI using the anti-CD2 antibodies T11 and preimplantation factor peptides |
| US8222211B2 (en) | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
| US7723289B2 (en) * | 2003-10-22 | 2010-05-25 | Bioincept, Llc | PIF tetrapeptides |
| US7723290B2 (en) * | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
| CN102781958B (zh) * | 2009-12-05 | 2017-07-11 | 马尔瓦有限责任公司 | 基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗 |
| WO2012119072A2 (en) | 2011-03-02 | 2012-09-07 | Bioincept, Llc | Compositions and methods for treatment of intracellular damage |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| CA2996874A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
| EP3341739A4 (de) | 2015-08-28 | 2019-07-10 | BioIncept LLC | Mutierte peptide und verfahren zur behandlung von subjekten damit |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
| GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| US5972351A (en) * | 1992-04-03 | 1999-10-26 | Isis Innovation Limited | Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens |
-
1994
- 1994-03-31 GB GB9406492A patent/GB9406492D0/en active Pending
-
1995
- 1995-03-30 DE DE69520943T patent/DE69520943T2/de not_active Expired - Fee Related
- 1995-03-30 WO PCT/GB1995/000737 patent/WO1995026982A2/en active IP Right Grant
- 1995-03-30 EP EP95913269A patent/EP0753009B1/de not_active Expired - Lifetime
- 1995-03-30 AT AT95913269T patent/ATE201215T1/de not_active IP Right Cessation
- 1995-03-31 JP JP7525507A patent/JPH09510877A/ja not_active Ceased
-
2005
- 2005-04-22 JP JP2005124999A patent/JP2006180865A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995026982A2 (en) | 1995-10-12 |
| EP0753009A1 (de) | 1997-01-15 |
| GB9406492D0 (en) | 1994-05-25 |
| WO1995026982A3 (en) | 1996-02-15 |
| EP0753009B1 (de) | 2001-05-16 |
| JPH09510877A (ja) | 1997-11-04 |
| DE69520943T2 (de) | 2001-11-08 |
| JP2006180865A (ja) | 2006-07-13 |
| ATE201215T1 (de) | 2001-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69520943D1 (de) | Malariapeptide | |
| Mahajan et al. | Multiple antigen peptide vaccines against Plasmodium falciparum malaria | |
| Miyahira et al. | Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice | |
| DE69833755D1 (de) | Verfahren zur herstellung von nicht-immunogenen proteinen | |
| ATE411043T1 (de) | Verfahren von dna-impfung | |
| ATE418340T1 (de) | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen | |
| Rosa et al. | The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate | |
| DE69333468D1 (de) | Schützende antikörper induzierende antigene aus plasmodium falciparum | |
| Calvo-Calle et al. | A linear peptide containing minimal T-and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge | |
| PE97298A1 (es) | Composicion para vacunas | |
| DK0859957T3 (da) | Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling | |
| ATE90388T1 (de) | Schuetzendes peptid-antigen. | |
| Franke et al. | A subdominant CD8+ cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture | |
| Holder et al. | Human immune response to MSP-1 | |
| BenMohamed et al. | Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides | |
| TIAN et al. | Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria | |
| Perlaza et al. | Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice | |
| Céspedes et al. | Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct | |
| ATE352315T1 (de) | Neospora impstoff | |
| DK218886A (da) | Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner | |
| BR9604989A (pt) | Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção | |
| Tucker et al. | Pre-erythrocytic vaccine candidates in malaria | |
| US20020136733A1 (en) | Malaria peptides | |
| Huynh Quan Dat et al. | Mimicking a conformational B cell epitope of the heat shock protein PfHsp70‐1 antigen of Plasmodium falciparum using a multiple antigenic peptide | |
| Rathore et al. | Disruption of disulfide linkages of the Plasmodium falciparum circumsporozoite protein: effects on cytotoxic and antibody responses in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: OXXON THERAPEUTICS LTD., OXFORT, GB |
|
| 8339 | Ceased/non-payment of the annual fee |